The results found that CD68 protein expression was not significantly correlated with clinicopathological features (age, sex, tumour size, etc), patients with high CD86 expression showed a remarkably lower presence of poorer differentiation (P =.047) and more advanced tumour staging (TNM stage, P =.017), and not significantly associated with age, sex, tumour location, tumour size, T stage, lymph node metastasis and distant metastasis. This evidence concerns the gene CD86 and metastatic malignant neoplasm in the lymph nodes.